Evidence supports the notion that the urinary excretransplantation.
strated a dissociation of their excretory pattern in the Results. The rate of TXA 2 biosynthesis (urinary 11-dehydro-TXB 2 excretion largely reflects platelet TXA 2 production in setting of renal disease [5] . Moreover, urinary excretion vivo) was significantly (P Ͻ 0.0001) higher in RTRs than in of enzymatic thromboxane metabolites is increased in healthy subjects. Plasma von Willebrand factor (vWF) and patients with in vivo platelet activation [6] [7] [8] .
thrombin-antithrombin (TAT) complexes were significantly Increased urinary excretion of 2,3-dinor-TXB 2 has higher (P Ͻ 0.001) in RTRs compared with controls. Urinary 11-dehydro-TXB 2 directly correlated with plasma vWF and been reported in cyclosporine A nephrotoxicity (CsA) cholesterol. We next examined the relative influence of in rats [9] and in humans [10] . Because in vitro CsA did cyclosporine A (CsA) on TXA 2 biosynthesis and endothelial not interfere with platelet arachidonic acid metabolism activation, comparing a group of RTRs not receiving CsA with in rats [9] , it has been suggested that the cause of the an age-and sex-matched group of patients treated with CsA. Urinary excretion of 11-dehydro-TXB 2 and plasma levels of increased urinary excretion of 2,3-dinor-TXB 2 is the con-vWF were significantly increased in RTRs who received CsA sequence of intrarenal platelet activation, triggered by compared with those who did not. After an overall follow-up endothelial damage. of 120 months, RTRs who experienced cardiovascular events had a higher frequency of abnormal plasma levels of vWF than Plasma measurements of von Willebrand factor (vWF) patients who remained event free. may give a good indication of the degree of endothelial Conclusion. Renal transplantation is associated with in vivo perturbation [11] . It is synthesized by endothelial cells platelet activation highly related to endothelial activation. This and secreted via constitutive and inducible pathways trigis particularly evident in CsA-treated patients. Administration of drugs that are able to reduce or eliminate thromboxanegered by exposure to a wide array of inflammatory medidependent platelet activation in vivo may be beneficial to reators [11]. In particular, vWF is an adhesive multimeric duce the risk of cardiovascular events in RTRs. glycoprotein, also contained in platelets and megakaryocytes, that regulates platelet adhesion to the subendothelium [11] . Accelerated arterial disease is a leading cause of mor-
The aims of this study were as follows: (1) to evaluate tality in long-term survivors of renal transplantation [1] .
the rate of thromboxane biosynthesis in a relatively large group of renal transplant recipients (RTRs) and controls in this setting; (3) to explore the interplay between markers of endothelial damage, thrombin generation, and them were hypertensive (N ϭ 44) and were treated with ␤ blockers or diuretics. All patients were taking prednisone (5 to 20 mg/day) or azathioprine (25 to 125 mg/day). All but 10 were taking cyclosporine A (1.6 to 6.1 mg/kg/ platelet activation; and (4) to examine the relative influday). This group of 10 RTRs (Table 2 ) underwent renal ence of cyclosporine treatment on these parameters. transplantation before CsA was widely employed, and they were available for study only 31 to 145 months after surgery. METHODS
Subjects
Follow-up Sixty-five consecutive patients (24 women and 41 men,
The vital status of the study patients was reviewed aged 41 Ϯ 11 years, range 22 to 60 years) who had annually for 10 years to verify the occurrence of major undergone cadaveric renal transplantation within the endpoints. For the survival analysis, myocardial inprevious 57 Ϯ 35 months (range 2 to 145 months) and farction, cardiac death, and need of hemodialysis were 20 age-matched healthy subjects (7 women and 13 men, considered major end points. Nonfatal myocardial inaged 42.3 Ϯ 11.3 years, range 21 to 57 years) were asked farction (MI) was defined as rapid onset of typical sympto participate in the study (Table 1) . Informed consent toms consistent with acute MI plus either typical electrowas obtained from each participating subject. The intercardiographic changes (including new Q waves) or a nal medicine review board of our institutions approved significant serum enzyme increase. Fatal MI was conthe study protocol.
firmed by a death certificate diagnosis plus preterminal Specific exclusion criteria included the following: clinihospitalization, with a definite or suspected diagnosis of cal evidence of acute or ongoing allograft rejection, the MI within four weeks of death. Cardiac death was depresence of serious systemic disease unrelated to the fined as a death within 24 hours of the onset of severe kidney, thrombocytopenia or a history of any disorder cardiac symptoms, unrelated to other known causes. associated with bleeding, a history of coronary heart Analyses disease, diabetes mellitus, elevated serum liver enzymes, and inability to refrain from the use of nonsteroidal anti-Urine was collected from each subject during the 12inflammatory agents (NSAIDs) for two weeks prior the hour period preceding blood sampling; the samples were frozen immediately and kept at Ϫ20ЊC until extraction. study. Immunoreactive 11-dehydro-TXB 2 was extracted from 20 mL urine aliquots and measured by a previously valiby the Spearman rank correlation test. Prognostic values dated radioimmunoassay technique [7, 8] .
of the variables under study were assessed by Kaplan-Blood samples were obtained by standard venopunc-Meier method and were compared by long-rank test. All ture after a 12-hour fast. Whole blood was immediately values are reported as means Ϯ 1 SD. Statistical signifianticoagulated with ethylenediaminetetraacetic acid cance was considered to be indicated by a value of P Ͻ (EDTA; 1 mg/mL) and centrifuged at 3000 ϫ g at 4ЊC 0.05. All calculations were made with the computer profor 10 minutes to obtain plasma. Samples were frozen at gram Stat View (Abacus Concepts, Berkeley, CA, USA). Ϫ20ЊC until assayed. Plasma concentrations of thrombinantithrombin complexes (TAT) were measured with an enzyme immunoassay (Behringwerke AG, Marburg, RESULTS Germany), as previously described [12] . Plasma vWF Baseline characteristics of RTRs are shown in Table 1 . antigen was determined with an enzyme immunoassay
The rate of TXA 2 biosynthesis, as reflected by the (Asserachrom vWF-Ag; Boehringer Mannheim, Mannexcretion of its major enzymatic metabolite, 11-dehydroheim, Germany) as previously described [13] . For all TXB 2 , was significantly (P Ͻ 0.0001) higher in RTRs assays, interassay and intra-assay coefficients of variation (2055 Ϯ 1498 pg/mg creatinine; median, 1408; range, were Ͻ8%. 161 to 7200) than in healthy subjects (329 Ϯ 132 pg/mg All blood samples for the lipid studies were collected creatinine; median, 284; range, 165 to 582). In 54 (83%) in tubes containing EDTA 1 mg/mL and separated of the 65 patients, metabolite excretion was more than within one hour after sampling. Total cholesterol (TC) two standard deviations above the control mean (Fig. 1) . and triglycerides were determined by an enzymatic Plasma vWF was significantly (P Ͻ 0.001) increased method. High-density lipoprotein-cholesterol (HDL-C)
in RTRs compared with those in healthy subjects (178 Ϯ was measured after phosphotungstic acid/MgCl 2 precipi-55 vs. 110 Ϯ 13%). In 45 (69%) of the 65 patients, plasma tation on fresh plasma. Low-density lipoprotein-choles-vWF was more than two standard deviations above the terol (LDL-C) was calculated by the Friedewald's forcontrol mean. Plasma TAT complexes were significantly mula. Apolipoprotein (Apo) B and A1 were measured higher in RTRs (4.6 mg/L; range, 1.7 to 28; P Ͻ 0.001) by nephelometric method. These procedures have been compared with healthy individuals (2.4 mg/L; 1.7 to 4.12). described in detail elsewhere [7, 13] .
Urinary 11-dehydro-TXB 2 directly correlated with Statistical analysis plasma vWF ( ϭ 0.84, P ϭ 0.0001; Fig. 2 ). No correlation was found between thromboxane metabolite excretion The data were analyzed by nonparametric methods to and TAT levels. However, a weak direct correlation was avoid assumptions about the distribution of the meafound between vWF and TAT levels ( ϭ 0.32, P ϭ 0.009). sured variables. An analysis of variance (ANOVA) was Urinary 11-dehydro-TXB 2 directly correlated with performed with the Kruskal-Wallis method. Subsequent plasma TC ( ϭ 0.39, P ϭ 0.001), LDL-C ( ϭ 0. 39, P ϭ pair-wise comparisons were made with the Mann-Whitney 0.001), and Apo B levels ( ϭ 0.32, P ϭ 0.0091). U test. Moreover, the association of eicosanoid measurements with other biochemical parameters was assessed Because cyclosporine A has been associated with in-creased urinary excretion of TXB 2 and 2,3-dinor-TXB 2 , we next examined the relative influence of immunosuppressant therapy on TXA 2 biosynthesis and endothelial activation. Ten RTRs (3 women and 7 men, aged 42 Ϯ 10 years) who never received CsA were matched for sex, age, and months after surgery with 10 RTRs who received CsA ( Table 2 ). The two groups of patients were comparable for lipid parameters and dialysis time. The RTRs who did not receive CsA (group I) were studied 80 Ϯ 35 months after surgery in comparison to 55 Ϯ 31 months of the group II that received CsA (P ϭ 0.0506). Urinary excretion of 11-dehydro-TXB 2 was significantly increased in group II (3067 Ϯ 2003 pg/mg creatinine) compared with both controls (344 Ϯ 142, P ϭ 0.0004) and group I (979 Ϯ 477 pg/mg creatinine, P ϭ 0.0047). Patients who received CsA also had higher levels of vWF compared with controls and those of patients who did not receive CsA (213 Ϯ 51 vs. 107 Ϯ 10, P ϭ 0.0064, and vs. 151 Ϯ 36%, P ϭ 0.0011, respectively; Fig. 3 ).
Plasma levels of TAT were not significantly increased in group II (3.8 mg/L, range 2.3 to 15) compared with those in group I (4.0 mg/L, 2 to 28); meanwhile, control subjects had significantly lower plasma levels (2.3 mg/L, 1.7 to 4.1; P ϭ 0.013) than the CsA-treated group.
Follow-up
The overall duration of follow-up was of 120 (109 Ϯ 23; range 14 to 120) months. One patient died from lung cancer, and three patients were lost to follow-up because they refused to undergo the scheduled visits. These four patients were excluded from the survival analysis.
During a median follow-up of 90 (86 Ϯ 29; range 14 to 120) months, 16 patients experienced major endpoints. There were five cardiac deaths, six acute myocardial infarctions (1 fatal and 5 nonfatal), and five patients who needed hemodialysis. These patients had a similar follow-up had a higher frequency of abnormal vWF plasma levels (94 vs. 67%, P ϭ 0.03) at the baseline than patients who remained event free. In particular, all patients who experienced acute myocardial infarction or DISCUSSION cardiac death during the follow-up had abnormal vWF Cardiovascular disease is the major cause of mortality plasma levels at the baseline. Among patients who in RTRs [14] [15] [16] [17] . The high rate of cardiovascular disease needed hemodialysis, all but one showed baseline vWF has been due to a cluster of risk factors, including dyslipivalues more than two standard deviations above the condemia and hypertension [18, 19] . trol mean.
Because thromboxane-dependent platelet activation Univariate analysis of survival showed that plasma has been considered responsible for, or at least a contribvalues of vWF in excess of the mean Ϯ 2 SD of control utor of, acute thromboembolic complications such as subjects was significantly related to cumulative endpoints myocardial infarction and ischemic stroke [17], we (log rank ϭ 3.8, P Ͻ 0.05) as well as to cardiovascular events (log rank ϭ 4.2, P Ͻ 0.04).
sought to determine whether the systemic formation of thromboxane A 2 is altered in vivo through measurement mal levels of vWF and TAT, an index of thrombin generof a major metabolite (11-dehydro-TXB 2 ) in the urine ation, in RTRs with enhanced thromboxane biosynthesis of RTRs. In fact, native unmetabolized TXB 2 in urine provides in vivo evidence for the concomitant occurrence reflects thromboxane production by the kidney, while 11of these events, and suggests that platelet activation and dehydro-TXB 2 or 2,3-dinor-TXB 2 primarily may reflect thrombin generation may be a consequence of endothesystemic thromboxane biosynthesis [2-8, 20, 21] . Endolial damage or dysfunction. thelial cell activity was evaluated in vivo by determina-Based on current evidence, vascular complications tion of circulating levels of vWF, synthesized and semight be a consequence of long-standing endothelial increted by the endothelial cells. vWF is an adhesive jury and the accompanying platelet activation and thrommultimeric glycoprotein, also contained in platelets and bin generation. megakaryocytes, that regulates platelet adhesion to the We also report the first evidence, to our knowledge, subendothelium [11] . The circulating vWF pool is dethat RTRs who received cyclosporine had significantly rived mainly from endothelial cells [11] , and high plasma higher in vivo platelet and endothelial activation than vWF levels have been proposed as a marker of endothe-RTRs who were not on CsA immunosuppression. Inlial damage [11, 22] . creased urinary excretion of 2,3-dinor-TXB 2 has been Sixty-nine percent of our patients showed plasma levpreviously demonstrated in rat [9] and human [10] CsA els of vWF more than two standard deviations above nephrotoxicity. In vitro CsA did not interfere with platethe control mean, strongly indicating that vascular endolet thromboxane generation when rat platelet-rich plasma thelium is altered in RTRs. Elevated levels of vWF have was exposed to CsA and then challenged with adenosine been described earlier in CsA-treated RTRs [23]. In diphosphate (ADP) or arachidonate [9] . However, in this report, we provide biochemical evidence for the humans, Jorkasky et al reported increased production occurrence in RTRs of thromboxane-dependent platelet of thromboxane by platelets exposed to cyclosporine activation in vivo, and demonstrate that this activation [28] , and cyclosporine may activate platelet arachidonate is highly related to peripheral signs of altered endothelial metabolism in the systemic circulation directly [29] [30] [31] . cell function. Moreover, the follow-up data suggest that Moreover, by increasing the production of reactive oxyendothelial perturbation may represent a link between gen species, CsA may induce endothelial damage in vivo platelet activation and the occurrence of cardio- [32] [33] [34] , at the renal circulation activating platelets and vascular events. macrophages during their passage through the renal cir-This process may be exacerbated by the frequent occulation. On the other hand, human platelets exposed currence of hyperlipidemia after transplantation [24] .
to cyclosporine have an impaired ability to mediate vaso-Hyperlipidemia may be due to alterations in metabolism dilation. This appears to be caused by a compound reand nutritional status that occur after successful transleased by cyclosporine-exposed platelets that interferes plantation, with reversal of chronic renal failure. Morewith nitric oxide-dependent vasodilation [35] . over, drugs used for immunosuppression and the frequent
In conclusion, we have characterized an exquisitely use of diuretics and ␤ blockers to treat hypertension sensitive marker of platelet activation, which is abnormal induced by cyclosporine may also affect lipoprotein mein approximately 80% of RTRs even several months tabolism [25] . Because abnormal cholesterol levels are after surgery. Although the mechanisms responsible for related to persistent thromboxane-dependent platelet platelet activation are likely to be multifactorial in this activation [26], we correlated urinary 11-dehydro-TXB 2 disease (for example, endothelial injury, disease-or treatlevels to cholesterol or LDL-C levels in RTRs. The weak ment-related metabolic disorders), we show that renal correlation between the two suggests that thromboxanetransplantation is associated with in vivo platelet activadependent platelet activation is only partly a consetion and highly related to endothelial activation. This is quence of abnormal cholesterol levels.
particularly evident in the CsA-treated patients. More-Renal transplant recipients show increased plasma over, the follow-up study showed that plasma vWF levels TAT complexes, consistent with coagulative activation are significantly related to cardiovascular endpoints. in vivo. In fact, TAT complexes result from the neutral-
The analytical approach we have used may help idenization of thrombin by its principal naturally-occurring tify those patients at increased thrombotic risk as poteninhibitor [27] . However, the lack of correlation between tial candidates for antiplatelet therapy [20] . Of course, urinary excretion of 11-dehydro-TXB 2 and plasma TAT long-term, prospective clinical studies are needed to verify complexes excludes that increased thrombin generation the validity of the proposed sequence of events and to induces platelet activation. Platelet and coagulative actidetermine the prognostic value of abnormal thromboxvation may be related to the presence of endothelial ane biosynthesis vis-à -vis other indexes of vascular inactivation, as demonstrated by the correlation between jury, including vWF levels. Moreover, controlled clinical plasma vWF levels and both urinary 11-dehydro-TXB 2 and plasma TAT levels. Therefore, our finding of abnor-trials of low-dose aspirin may help define the pathophysio-
